Stay updated with breaking news from Single Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo, with treatment with ...
- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR
- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation –BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-...
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six month follow-up analysis, compared to ...